Please login to the form below
Combination treatment
This page shows the latest Combination treatment news and features for those working in and with pharma, biotech and healthcare.
GSK shares positive phase 3 results for Blenrep combination in multiple myeloma
GSK has shared positive results from a late-stage trial of its BCMA-targeting antibody-drug conjugate Blenrep (belantamab mafodotin) as a second-line treatment for relapsed or refractory multiple myeloma. ... The DREAMM clinical development programme
Latest news
-
Merck receives FDA approval for Keytruda combination in gastric cancer
Last month, the therapy was approved in the US as part of a combination treatment for patients with earlier stages of lung cancer. ... to prepare patients for the surgical removal of their tumour and then as a single agent as an adjuvant treatment after
-
Vaccitech renames as Barinthus Biotherapeutics to focus on immunotherapy
The company is currently studying the candidate in combination with other agents, including siRNA and low-dose anti-PD-1 antibodies, to control infection, counteract immune suppression and treat T cell ... The open-label phase 2b study has been
-
Takeda’s Fruzaqla receives FDA approval for metastatic colorectal cancer
The FDA’s decision makes Fruzaqla the first targeted treatment options approved in the US for metastatic CRC regardless of biomarker status or prior therapies in more than a decade and ... The US approval comes just a few weeks after Takeda announced
-
Merck shares positive results for adjuvant Keytruda in phase 3 kidney cancer trial
This month, the therapy was approved by the US Food and Drug Administration in combination with chemotherapy to treat biliary tract cancer. ... Keytruda was also recently approved in the US as part of a combination treatment for patients with earlier
-
Merck’s Keytruda combination granted FDA approval for biliary tract cancer
at which point they are not eligible for surgery and face poor survival outcomes with limited treatment options. ... Last month, the therapy was approved in the US as part of a combination treatment for patients with earlier stages of lung cancer.
More from news
Approximately 0 fully matching, plus 379 partially matching documents found.
Latest Intelligence
-
The impact of prostate cancer on global health
PME: With a number of similar drugs currently being developed for combination treatment with novel hormone agents used in prostate cancer, how has drug development for this disease improved in the ... It is therefore critical to research novel treatment
-
Tuberculosis – why it remains a major global public health challenge
TB combination treatment regimens into phase 2 clinical development. ... The MRI will conduct non-clinical and clinical studies of these candidates to determine their potential for inclusion in new affordable combination treatment regimens for TB with
-
As COVID-19 takes over the world, biopharma fights back
A combination HIV treatment: AbbVie’s Kaletra. In an unprecedented move, AbbVie has suspended its patents on its combination HIV drug Kaletra, after it was identified as having potential against ... The combination drug was first included in Chinese
-
Deal Watch April 2016
Another deal worth pondering about is the $265m exclusive license by AstraZeneca (AZ) of the approved Zurampic (lesuranid) plus a fixed dose combination with allopurinol for treatment of gout. ... 85 . Dong A (SK). Tobira (US). Cross license. Evogliptin
-
Pharma deals in April 2015
No deal terms were disclosed. The initial development plan will look at the combination therapy as a potential treatment for NHL. ... The treatment combines an antibody engineered to target CD19 with the cancer-killing agent maytansinoid.
More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.
Latest from PMHub
-
Listening and hearing - how patients’ online behaviour can help us to improve wellbeing in psoriasis.
Frequently raised concerns form patients include embarrassment and social anxiety in relation to their skin, and the positive impact that effective treatment can have in combination with maintaining good mental health.
-
What does the future hold for Light-chain Amyloidosis?
approval in combination with CyBorD for the treatment of newly diagnosed adult patients with AL amyloidosis. ... Prior to the approval of a new combination treatment for use across Europe, we conducted the first wave of our research to generate a
-
Oncosec
body. OncoSec has built a deep and diverse clinical pipeline utilizing TAVO as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors; ... Results from recently completed
-
Marketing strategy in complex environments
The last few years have seen influential scientific advances, resulting in subtle shifts in how pharma tackles disease treatment. ... The treatment of aggressive diseases often benefits very noticeably from combination therapy, especially when involving
More from PMHub
Approximately 1 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
- Pfizer’s RSV vaccine granted MHRA approval to protect infants and older adults
- Novavax’s updated COVID-19 vaccine granted Emergency Use Listing by WHO
- FDA to investigate risk of T-cell malignancy from CAR-T cell immunotherapies
- Boehringer Ingelheim and IBM announce AI antibody drug discovery partnership
- New blood test to reduce heart attacks and death rates in A&E heart patients
- Clairvoyant commercialisation
No results were found
PMHub
KVA
KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...
Latest intelligence
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
- The rise of digital healthcare – fuelled by open innovation in healthtech hubs
- How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...
